Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
EPS Growth %: -50.0%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -50.0%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
- JPMorgan Starts Bechtle AG (BC8:GR) (BECTY) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
